A controlled trial of intravenous immunoglobulin G in chronic fatigue syndrome

Peterson, Phillip K.; Shepard, Judy; Macres, Mark; Schenck, Carlos H.; Crosson, John T.; Rechtman, David J.; Lurie, Nicole

doi:10.1016/0002-9343(90)90172-a

Cited by 146 publications

(48 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…26 The largest of these 5 RCTs reported no effect of the intervention. 28 Two small RCTs evaluated interferon; 1 of these found an overall beneficial effect 29 and the other showed some positive effects, although these were in relation to immunological outcomes only.…”

Section: Immunological Resultsmentioning

confidence: 99%

Interventions for the Treatment and Management of Chronic Fatigue Syndrome

Whiting¹,

Bagnall²,

Sowden³

et al. 2001

JAMA

448

273

View full text Add to dashboard Cite

Overall, the interventions demonstrated mixed results in terms of effectiveness. All conclusions about effectiveness should be considered together with the methodological inadequacies of the studies. Interventions which have shown promising results include cognitive behavioral therapy and graded exercise therapy. Further research into these and other treatments is required using standardized outcome measures.

show abstract

Section: Immunological Resultsmentioning

confidence: 99%

Interventions for the Treatment and Management of Chronic Fatigue Syndrome

Whiting¹,

Bagnall²,

Sowden³

et al. 2001

JAMA

448

273

View full text Add to dashboard Cite

show abstract

“…In a similar study of 24 infants and children with immune thrombocytopenic purpura, the adverse effects were also mild and included headache, nausea, vomiting, and fever; however, aseptic meningitis and anaphylactoid reactions occurred in 1 patient each [11]. In addition, adverse reactions have been reported to be rare in the treatment of very-low-birth-weight infants with IVIg [12] and were observed in 20% of both the placebo and the IVIg treatment groups in a trial performed on the use of IVIg in chronic fatigue syndrome [13]. The different rates of adverse reactions in these studies depend on many factors such as different indications for IVIg use, infusion rate, IVIg dose, or even patients' age.…”

Section: Discussionmentioning

confidence: 99%

Adverse Effects of Intravenous Immunoglobulin Therapy in 56 Patients with Autoimmune Diseases

et al. 2001

View full text Add to dashboard Cite

Objective: To test the adverse effects and viral safety of intravenous immunoglobulin (IVIg) use in autoimmune diseases. Methods: Fifty-six patients with various autoimmune diseases who were treated with one to six IVIg courses were evaluated for the presence of adverse effects following IVIg therapy and were screened before and after the treatment for the presence of serum human immunodeficiency virus antibodies, hepatitis C virus antibodies, and hepatitis B surface antigen. Results: Among the 56 patients, 20 (36%) had at least one adverse effect following at least one of the treatment courses. These included headache, low-grade fever, chills, anemia, low-back pain, transient hypotension, nausea, intensified perspiration, and superficial and deep vein thromboses. Whereas the presence of adverse effect to IVIg was unrelated to either the clinical response to the treatment or to the nature of the autoimmune disease, the occurrence of an adverse effect in the first treatment course was significantly associated with a greater chance for an adverse effect in the subsequent courses. No transmission of any of the three viral agents examined could be detected. Conclusions: Although IVIg use in autoimmune diseases is associated with adverse effects in about one third of the patients, these effects are usually mild and transient. Patients who develop adverse effects during the first treatment course may be at increased risk of adverse effects during the subsequent IVIg courses.

show abstract

“…6 However, only a few of these agents have been subjected to testing in randomized, placebo-controlled trials. The selection of drugs for these trials has been influenced by prevailing hypotheses regarding the cause or pathogenesis of CFS, eg, persistent viral infection, 7 immunologic or allergic disorders, [8][9][10][11] vitamin deficiency, 12 or depression. 13 Even though clinical benefit has been reported in some of these trials, 8,10 concerns about study methods have precluded their general acceptance.…”

mentioning

confidence: 99%